Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Vivek Reddy

Clinical Cardiac Electrophysiology New York, NY Medical Doctor

NPI 1083672463 CMS profile 230570

5 E 98Th St, 3Rd Floor, New York, NY 10029

Open in the dashboard

General payments

$14,901,388

524 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$1,215,665

7 holdings reported · through program year 2025

Research they led as principal investigator

$1,726,149 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Vivek Reddy of New York, NY is reported in the CMS Open Payments database as having received $14,901,388 across 524 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $1,726,149 in research payments, paid to institutions rather than to them. They also declared ownership or investment interests valued at $1,215,665 across 7 holdings.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Clinical Cardiac Electrophysiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

14 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,557,291 94
2024 General $1,190,756 111
2023 General $1,858,841 96
2022 General $8,646,794 114
2021 General $1,325,934 29
2020 General $203,026 24
2019 General $118,745 56
2025 Ownership $109,830 1
2024 Ownership $147,525 1
2023 Ownership $215,861 1
2022 Ownership $187,417 1
2021 Ownership $234,469 1
2020 Ownership $167,914 1
2019 Ownership $152,649 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Vivek Reddy
  • Clinical Cardiac Electrophysiology median
  • Middle half of Clinical Cardiac Electrophysiology
  • National median

In program year 2025, general payments to Vivek Reddy were reported at $1,557,291. Among 3,064 Clinical Cardiac Electrophysiology profiles paid that year, the median was $2,462 and the middle half received between $733 and $7,710.

Show as a table
Year Vivek Reddy Clinical Cardiac Electrophysiology median Middle half National median
2019 $118,745 $2,361 $585–$8,260 $163
2020 $203,026 $993 $247–$4,351 $114
2021 $1,325,934 $1,185 $326–$4,739 $132
2022 $8,646,794 $2,073 $554–$6,789 $149
2023 $1,858,841 $2,568 $759–$8,159 $160
2024 $1,190,756 $2,557 $703–$7,403 $164
2025 $1,557,291 $2,462 $733–$7,710 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $10,301,975 53 payments
  2. Boston Scientific Corporation $3,643,899 196 payments
  3. Ethicon Inc. $276,022 4 payments
  4. Biosense Webster, Inc. $198,454 25 payments
  5. Abbott Laboratories $94,346 130 payments
  6. Circa Scientific, Inc. $87,900 2 payments
  7. Adagio Medical, Inc. $73,617 15 payments
  8. Substrate HD $72,158 1 payment
  9. Acutus Medical, Inc. $67,462 17 payments
  10. Pulse Biosciences, Inc. $42,000 14 payments
  11. Other $43,555 67 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Acquisitions $13,758,164 16 payments
  2. Consulting Fee $609,506 73 payments
  3. Travel and Lodging $201,034 146 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $191,598 27 payments
  5. Current or prospective ownership or investment interest $94,834 2 payments
  6. Food and Beverage $22,142 245 payments
  7. Grant $11,639 4 payments
  8. Honoraria $10,000 4 payments
  9. Royalty or License $2,291 1 payment
  10. Education $181 6 payments
Products named General payments · program years 2019–2025
  1. General - Therapies $1,402,835 9 payments
  2. GENERAL EP $1,163,862 2 payments
  3. GENERAL - EP $810,748 5 payments
  4. General Therapies $91,305 2 payments
  5. Volta AF-Xplorer $72,158 1 payment
  6. Farapulse $55,507 3 payments
  7. CellFx $42,000 14 payments
  8. AVEIR $26,334 26 payments
  9. Carto 3 $22,181 16 payments
  10. WATCHMAN Access System $16,878 29 payments
  11. Other $149,104 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 6 drugs

Part D claims

235

Median for Cardiology: 2,533

Drug cost

$113,902

Median for Cardiology: $485,213

Branded share of claims

52.8%

Median for Cardiology: 25.7%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 65 $57,838
Xarelto Rivaroxaban Brand 27 $26,935
Multaq Dronedarone Hcl Brand 19 $24,877
Colchicine Generic 72 $3,463
Metoprolol Succinate Generic 39 $420
Diltiazem 24hr Er (Cd) Diltiazem Hcl Brand 13 $368

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,782 Part D prescribers listed as Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$541,687

Medicare's payments for the services billed

Medicare patients

1,420

Average age 78

Services billed

4,510

573 women, 847 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Atrial fibrillation 72%
Ischemic heart disease 57%
Arthritis 51%
Heart failure 42%
Diabetes 37%
Chronic kidney disease 26%
Cancer 19%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XARELTO
  • Janssen Pharmaceuticals, Inc $17
$17 27 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

524 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Cardiac Electrophysiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record